David A. Siegel Akebia Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 151,849 shares of AKBA stock, worth $302,179. This represents 0.0% of its overall portfolio holdings.

Number of Shares

151,849

Previous 159,949 5.06%

Holding current value

$302,179

Previous $292,000 47.26%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $6,966 - $13,203	-8,100 Reduced 5.06%	151,849 $154,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.24 $8,890 - $15,680	-7,000 Reduced 4.19%	159,949 $292,000
Q4 2023 Feb 14, 2024	SELL	$0.8 - $1.28 $5,200 - $8,320	-6,500 Reduced 3.75%	166,949 $207,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $2,697 - $5,704	3,100 Added 1.82%	173,449 $197,000
Q2 2023 Aug 14, 2023	SELL	$0.51 - $1.43 $24,480 - $68,640	-48,000 Reduced 21.98%	170,349 $156,000
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $672 - $1,380	1,200 Added 0.55%	218,349 $122,000
Q4 2022 Feb 14, 2023	BUY	$0.25 - $0.58 $300 - $696	1,200 Added 0.56%	217,149 $125,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $7,620 - $11,684	-25,400 Reduced 10.52%	215,949 $68,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $31,392 - $65,727	-98,100 Reduced 28.9%	241,349 $85,000
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $44,064 - $179,316	-61,200 Reduced 15.28%	339,449 $244,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $85,330 - $126,108	37,757 Added 10.4%	400,649 $905,000
Q3 2021 Nov 15, 2021	BUY	$2.35 - $3.88 $8,225 - $13,580	3,500 Added 0.97%	362,892 $1.05 Million
Q2 2021 Aug 16, 2021	SELL	$2.83 - $4.2 $1.73 Million - $2.56 Million	-609,753 Reduced 62.92%	359,392 $1.36 Million
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $1.79 Million - $3.11 Million	614,617 Added 173.36%	969,145 $3.28 Million
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $80,070 - $136,337	-36,068 Reduced 9.23%	354,528 $993,000
Q3 2020 Nov 16, 2020	BUY	$2.39 - $13.08 $473,208 - $2.59 Million	197,995 Added 102.8%	390,596 $980,000
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $1.1 Million - $2.24 Million	164,995 Added 597.68%	192,601 $2.62 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $113,184 - $282,685	27,606 New	27,606 $209,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $360,096 - $515,460	-48,400 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $313,845 - $388,962	-34,300 Reduced 41.48%	48,400 $483,000
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $15,247 - $25,088	-1,600 Reduced 1.9%	82,700 $788,000
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $82,592 - $113,622	5,800 Added 7.39%	84,300 $1.25 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $1.03 Million - $1.54 Million	78,500	78,500 $1.54 Million

Others Institutions Holding AKBA

# of Institutions

111

Shares Held

55M

Call Options Held

554K

Put Options Held

246K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $366M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account